Vistagen: Pherine Candidate Proof Of Concept Continues With Fifth Indication
Vistagen Therapeutics, Inc.'s fasedienol shows promise in treating social anxiety; new results expected 2025. Click for my ...
Anavex: Looking At Different Statistical Approaches Before EMA Opinion
Anavex Life Sciences Corp.'s stock rises 50% as EMA reviews Alzheimer's drug blarcamesine. Click for my updated look at AVXL stock and why I have upgraded it.
Benitec Biopharma Inc.: Benitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational Update
Fifth Subject in BB-301 Phase 1b/2a Clinical Treatment Study safely treated in February 2025- -Interim clinical study update to be presented in late-breaking oral presentation at the 2025 Muscular Dys ...
Benitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational Update
Fifth Subject in BB-301 Phase 1b/2a Clinical Treatment Study safely treated in February 2025--Interim clinical study update to be presented in ...